Edition:
United Kingdom

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

17.52HKD
23 Feb 2018
Change (% chg)

HK$-0.22 (-1.24%)
Prev Close
HK$17.74
Open
HK$18.00
Day's High
HK$18.00
Day's Low
HK$17.30
Volume
14,384,640
Avg. Vol
21,651,956
52-wk High
HK$18.70
52-wk Low
HK$9.35

Chart for

About

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and... (more)

Overall

Beta: 0.81
Market Cap(Mil.): HK$81,366.01
Shares Outstanding(Mil.): 6,054.02
Dividend: 0.12
Yield (%): 0.89

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-CSPC Pharmaceutical Group Announces Drug Registration Approval Of "Paclitaxel For Injection (Albumin-Bound)"

* ‍"PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" GRANTED DRUG REGISTRATION APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION Source text for Eikon: Further company coverage:

12 Feb 2018

BRIEF-CSPC Pharmaceutical Group's Gastric Cancer Drug Granted Orphan-Drug Designation By U.S. FDA​

* ‍GROUP'S GASTRIC CANCER DRUG "DP303C" WAS GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA​ Source text for Eikon: Further company coverage:

06 Feb 2018

BRIEF-CSPC Pharmaceutical Group Says Unit's Listing Application To CSRC Was Accepted

* CSPC XNW SUBMITTED APPLICATION TO CSRC FOR PROPOSED A SHARE LISTING ON CHINEXT OF SZSE & RECEIVED NOTICE OF ACCEPTANCE

27 Dec 2017

BRIEF-CSPC Pharmaceutical Group Appoints ‍Li Chunlei As Executive Director ​

* ‍LI CHUNLEI WAS APPOINTED AS AN EXECUTIVE DIRECTOR OF COMPANY WITH EFFECT FROM 12 DECEMBER 2017.​

12 Dec 2017

BRIEF-CSPC Pharmaceutical Group announces change of shareholdings of substantial shareholder

* ‍Massive Giant Group transferred approximately 6.78% of total issued shares to Common Success International​ Source text for Eikon: Further company coverage:

17 Nov 2017

BRIEF-CSPC Pharmaceutical Group posts 9-month profit attributable of HK$‍2.04​ bln

* 9-month profit attributable HK$‍2.04​ billion versus HK$1.57 billion

15 Nov 2017

BRIEF-CSPC Pharmaceutical Group updates on approvals ​of granted clinical trial

* Group's "HA121-28" and "alprostadil liposome injection" were granted clinical trial approvals ​

05 Nov 2017

BRIEF-CSPC Pharmaceutical Group ‍to issue 189 mln placing shares at HK$12.44 per share​

* ‍shall issue 189 million placing shares at placing price of hk$12.44 per share​

12 Oct 2017

BRIEF-CSPC Pharmaceutical Group updates on trading halt

* ‍seeks trading halt pending release of announcement regarding placing of new shares under general mandate​ Source text for Eikon: Further company coverage:

12 Oct 2017

BRIEF-CSPC Pharmaceutical says‍ trading in shares of co has been halted

* ‍Trading in shares of co has been halted at 9:08 a.m. on oct 12 Source text for Eikon: Further company coverage:

12 Oct 2017

Earnings vs. Estimates